WINSTON-SALEM – October 31, 2026 -- Modoral Brands Inc., an operating company of Reynolds American Inc., received U.S. FDA Marketing Granted Orders for eight VELO nicotine pouch products, clearing a select set of SKUs for the U.S. market.

FDA authorizes eight VELO flavor and strength variants at 4 mg

The orders cover two product lines, each at 400 mg pouch size and 4 mg nicotine strength. VELO Mini Pouch is authorized in Crema, Lime, Orange Crema and Passion Fruit. VELO Mini Pouch 2 is authorized in Crema, Lime, Orange Crema and Cinnamon.

Berlin – October 30, 2026 -- All 34 digital health application (DiGA) companies surveyed by Bitkom report a worsening situation for manufacturers over the past two years, and 82% describe the deterioration as severe. Industry association Pharma Deutschland cited the findings in calling for reliable reimbursement and less bureaucracy for digital therapies.

TAIPEI – October 30, 2026 -- HanchorBio (TWSE: 7827) has received Taiwan Food and Drug Administration approval for the Investigational New Drug application for HCB303, its trispecific TIGIT-Fc ligand-trap fusion protein, following U.S. FDA clearance. The approval was granted to its wholly owned subsidiary, FBD Biologics Limited, and gives the asset regulatory authorization for clinical investigation in two jurisdictions.

Münster – October 30, 2026 -- The partners of the GET H2 initiative have published a seven-point paper setting out measures to remove the bottlenecks slowing Germany's hydrogen ramp-up, supplementing the impulse paper the Federal Ministry for Economic Affairs and Energy (BMWE) released on October 20.

Mumbai – October 30, 2026 -- The U.S. Food and Drug Administration has approved Sun Pharma's supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) in adults with active psoriatic arthritis (PsA), the first expansion of the IL-23 inhibitor beyond plaque psoriasis since its 2018 U.S. approval.

Munich – October 30, 2026 -- ClimatePartner has subjected its label for printers, "Print Product with Financial Climate Contribution", to independent third-party review since May 2026, in response to stricter EU rules on sustainability claims that have applied since 27 September 2026.

McLean – October 29, 2026 -- Appian's Appian Defense Cloud (ADC) has received Impact Level 5 (IL5) Provisional Authorization to Operate from the US Department of War (DOW), clearing the platform to handle the department's highest-sensitivity unclassified workloads.

The IL5 designation allows ADC to store and process DOW mission-critical data, controlled unclassified information and unclassified national security systems. ADC builds on Appian's existing IL5 Appian Government Cloud offering.

European Union – October 29, 2026 -- The Council of the European Union has confirmed Carlo Comporti as the next Chair of the European Securities and Markets Authority (ESMA), effective 1 November 2026. ESMA announced the appointment in the latest edition of its Spotlight on Markets newsletter, which covers September and October 2026.

Berlin – October 29, 2026 -- Germany's pharmacist federation ABDA is lobbying the Bundesrat to retain the pharmacy-only dispensing requirement. It argues that the emergency care reform passed by the Bundestag on October 15 would let physicians dispense medicines directly and weaken drug safety checks.

Burlington – October 29, 2026 -- The U.S. Food and Drug Administration has approved an expanded indication for Instylla's Embrace Hydrogel Embolic System (HES), covering embolization of peripheral arterial bleeds in vessels of 6 mm or less. Embrace HES is now the first and only liquid embolic approved for both peripheral arterial bleeds and hypervascular tumors, according to the privately held company. The product is commercially available in the U.S.